Merck Raises Vioxx, Arcoxia Guidance; Ex-U.S. Sales Spur Growth
Merck is raising its 2004 sales guidance for its global COX-2 inhibitor business to the $2.8 bil.-$3 bil. range based on faster than expected growth for Vioxx and Arcoxia.
Merck is raising its 2004 sales guidance for its global COX-2 inhibitor business to the $2.8 bil.-$3 bil. range based on faster than expected growth for Vioxx and Arcoxia.